COVID-19; mRNA vaccine; cutaneous adverse reaction; lipid nanoparticle; S protein

Lamprinou M, Sachinidis A, Stamoula E, et al. COVID-19 vaccines adverse events: potential molecular mechanisms. Immunol Res. 2023; 71(3): 356–372. doi: 10.1007/s12026-023-09357-5 Risma KA, Edwards KM, Hummell DS, et al. Potential mechanism of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol. 2021; 147(6): 2075–2082.e2. doi: 10.1016/j.jaci.2021.04.002 Ogata AF, Cheng C, Desjardins M, et al. Circulating severe respiratory syndrome coronavirus 2 (SARS-C0V-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin Infect Dis. 2022; 74(4): 715–718. doi: 10.1093/cid/ciab465 Li C, Lee A, Grigoryan L, et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat Immunol. 2022; 23(4): 543–555. doi: 10.1038/s41590-022-01163-9 Barrios Y, Franco A, Sanchez-Machin I, et al. The beauty of simplicity: Delayed-type hypersensitivity reaction to measure cellular immune responses in RNA-SARS-Cov-2 vaccinated individuals. Vaccines (Basel). 2021; 9(6): 575. doi: 10.3390/vaccines9060575 Klimek L, Bergmann KC, Brehler R, et al. Practical handling of allergic reactions to COVID-19 vaccines. Allergo J Int. 2021; 30(3): 79–95. doi: 10.1007/s40629-021-00165-7 Karikó K, Ni H, Capodici J, et al. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem. 2004; 279(13): 12542–12550. doi: 10.1074/jbc.M310175200 Tatematsu M, Funami K, Seya T, et al. Extracellular RNA sensing by pattern recognition receptors. J Innate Immun. 2018; 10(5–6): 398–406. doi: 10.1159/000494034 Ablasser A, Poeck H, Anz D, et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR 7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol. 2009; 182(11): 6824–6833. doi: 10.4049/jimmunol.0803001 Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol. 2013; 10(2): 103–106. doi: 10.1038/cmi.2012.61 Goubau D, Schlee M, Deddouche S, et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5’-diphosphate. Nature. 2014; 514(7522): 372–375. doi: 10.1038/nature13590 Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001; 413(6857): 732–738. doi: 10.1038/35099560 Kawai T, Akira S. Signaling to NF-kappaB by toll-like receptors. Trends Mol Med. 2007; 13(11): 460–469. doi: 10.1016/j.molmed.2007.09.002 Rehwinkel J, Tan CP, Goubau D, et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell. 2010; 140(3): 397–408. doi: 10.1016/j.cell.2010.01.020 Schlee M. Master sensors of pathogenic RNA–RIG-I like receptors-. Immunobiology. 2013; 218(11): 1322–1335. doi: 10.1016/j.imbio.2013.06.007 Gregorio J, Meller S, Conrad C, et al. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J Exp Med. 2010; 207(13): 2921–2930. doi: 10.1084/jem.20101102 Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. Immunity. 2013; 38(5): 855–869. doi: 10.1016/j.immuni.2013.05.007 Feng Q, Hato SV, Langereis MA, et al. MDA5 detects the double-stranded RNA replicative form in picornavirus-infected cells. Cell Rep. 2012; 2(5): 1187–1196. doi: 10.1016/j.celrep.2012.10.005 Anderson BR, Muramatsu H, Nallagatla SR, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010; 38(17): 5884–5892. doi: 10.1093/nar/gkq347 Andries O, Mc Cafferty S, De Smedt SC, et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015; 217: 337–344. doi: 10.1016/j.jconrel.2015.08.051 Meyer M, Huang E, Yuzhakov O, et al. Modified NRNA-based vaccines elicit rubust immune responses and protect guinea pig from ebola virus disease. J Infect Dis. 2018; 217(3): 451–455. doi: 10.1093/infdis/jix592 Van Gulck ER, Ponsaerts P, Heyndrickx L, et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood. 2006; 107(5): 1818–1827. doi: 10.1182/blood-2005-01-0339 Pardi N, Weissman D. Nucleoside modified RNA vaccines for infectious diseases. Methods Mol Biol. 2017; 1499: 109–121. doi: 10.1007/978-1-4939-6481-9_6 Pardi N, Muramatsu H, Weissman D, et al. In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol. 2013; 969: 29–42. doi: 10.1007/978-1-62703-260-5_2 Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203(2): 631–637. doi: 10.1002/path.1570 Sano H, Kase M, Aoyama Y, et al. A case of persistent, confluent maculopapular erythema following a COVID-19 mRNA vaccination is possibly associated with the intralesional spike protein expressed by vascular endothelial cells and eccrine glands in the deep dermis. J Dermatol. 2023; 50(9): 1208–1212. doi: 10.1111/1346-8138.16816 Ndeupen S, Qin Z, Jacobsen S, et al. The mRNA-LNP platform’s nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021; 24(12): 103479. doi: 10.1016/j.isci.2021.103479 Alameh MG, Tombácz I, Bettini E, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021; 54(12): 2877-2892.e7. doi: 10.1016/j.immuni.2021.11.001 Tahtinen S, Tong AJ, Himmels P, et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022; 23(4): 532–542. doi: 10.1038/s41590-022-01160-y Trougakos IP, Terpos E, Alexopoulos H, et al. Adverse effects of COVID-19 mRNA vaccines: The spike hypothesis. Trends Mol Med. 2022; 28(7): 542–554. doi: 10.1016/j.molmed.2022.04.007 Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: A review. Clin Exp Allergy. 2016; 46(7): 907–922. doi: 10.1111/cea.12760 Shah S, Prematta T, Adkinson NF, et al. Hypersensitivity to polyethylene glycols. J Clin Pharmacol. 2013; 53(3): 352–355. doi: 10.1177/0091270012447122 SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048) 2.6.4 PFIZER CONFIDENTIAL (Japanese). Available online: https://www.pmda.go.jp/drugs/2021/P20210212001/672212000_30300AMX00231_I100_2.pdf (accessed on 15 September 2022). McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfeizer COVID-19 vaccination: A registry-basedstudy of 414 patients. J Am Acad Dermatol. 2021; 85(1): 46. doi: 10.1016/j.jaad.2021.03.092 Bellinato F, Fratton Z, Girolomoni G, et al. Cutaneous adverse reactions to SARS-CoV-2 Vaccines: A systematic review and meta-analysis. Vaccines (Basel). 2022; 10(9): 1475. doi: 10.3390/vaccines10091475 Washrawirul C, Triwatcharikon J, Phannajit J, et al. Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2022; 36(11): 1947–1968. doi: 10.1111/jdv.18294 Robinson LB, Fu X, Hashimoto D, et al. Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines. JAMA Dermatol. 2021; 157(8); 1000–1002. doi: 10.1001/jamadermatol.2021.2114 Avallone G, Quaglino P, Cavallo F, et al. SARS-Co-2 vaccine-related cutaneous manifestations: A systematic review. Int J Dermatol. 2022; 61(10): 1187–1204. doi: 10.1111/ijd.16063 Tan SW, Tam YC, Pang SM. Cutaneous reactions to COVID-19 vaccines: A worldwide review. JAAD Int. 2022; 7: 178–186. doi: 10.1016/j.jdin.2022.01.011 Mahmood F, Cyr J, Li A, et al. Vesiculobullous and other cutaneous manifestations of COVID-19 vaccines: A scoping and narrative review. J Cut Med Surg. 2023; 27(3): 260–270. doi: 10.1177/12034754231156561 Klein SL, Flanagan KL. Sex differences in immune responses. Nature Rev Immunol. 2016; 16(10): 626–638. doi: 10.1038/nri.2016.90 Vaccaro M, Bertino L, Squeri R, et al. Early atypical injection-site reactions to COVID-19 vaccine: A case series. J Eur Acad Dermatol Venereol. 2022; 36(1): e24–e26. doi: 10.1111/jdv.17683 Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-CoV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022; 186(1): 142–152. doi: 10.1111/bjd.20639 Kultawanich K, Sampattavanich N. Local bullous reaction as a cutaneous reaction after mRNA-boosted vaccination in a post-COVID patient. Clin Case Rep. 2022; 10(11): e6610. doi: 10.1002/ccr3.6610 Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384(5): 403–416. doi: 10.1056/NEJMoa2035389 Jacobson MA, Zakaria A, Maung Z, et al. Incidence and characteristics of delayed injection site reaction to the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (Moderna) in a cohort of hospital employees. Clin Infect Dis. 2022; 74(4): 591–596. doi: 10.1093/cid/ciab518 Hoff NP, Freise NF, Schmidt AG, et al. Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction. Eur J Med Res 2021;26(1):98. doi: 10.1186/s40001-021-00557-z Higashino T, Yamazaki Y, Senda S, et al. Assessment of Delayed Large Local Reactions After the First Dose of the SARS-CoV-2 mRNA-1273 Vaccine in Japan. JAMA Dermatol. 2022; 158(8): 923–927. doi: 10.1001/jamadermatol.2022.2088 Hibino M, Ishihara T, Iwata M, et al. Delayed injection site reaction after mRNA-1273 vaccination in Japan: A retrospective, cross-sectional study. Open Forum Infect Dis. 2021; 8(10): ofab497. doi: 10.1093/ofid/ofab497 Fernandez-Nieto D, Hammerle J, Fernandez-Escribano M, et al. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. ‘COVID-arm’: a clinical and histological characterization. J Eur Acad Dermatol Venereol. 2021; 35(7): e425–e427. doi: 10.1111/jdv.17250 Niebel D, Wenzel J, Wilsmann-Theis D, et al. Single-center clinico-pathological case study of 19 patients with cutaneous adverse reactions following COVID-19 vaccines. Dermatopathology (Basel). 2021; 8(4): 463–476. doi: 10.3390/dermatopathology8040049 Kempf W, Kettelhack N, Kind F, et al. ‘COVID arm’—Histological features of a delayed-type hypersensitivity reaction to Moderna mRNA-1273 SARS-CoV2 vaccine. J Eur Acad Dermatol Venereol. 2021; 35(11): e730–e732. doi: 10.1111/jdv.17506 Guerrero AJ, Estirado AD, Quirós JC, et al. Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19. J Allergy Clin Immunol Pract. 2021; 9(10): 3811–3813. doi: 10.1016/j.jaip.2021.07.012 Gambichler T, Boms S, Susok L, et al. Cutaneous findings following COVID-19 vaccination: Review of world literature and own experience. J Eur Acad Dermatol Venereol. 2022; 36(2): 172–180. doi: 10.1111/jdv.17744 Ju T, Lim SYD, Tey HL. Non-allergic nature of vast majority of cutaneous adverse reactions to mRNA COVID-19 vaccines: implications on treatment and re-vaccination. J Eur Acad Dermatol Venereol. 2022; 36(11): e861-e862. doi: 10.1111/jdv.18340 Anvari S, Samarakoon U, Fu X, et al. Urticaria and/or angioedema secondary to mRNA COVID-19 vaccines: Updates from a United States case registry. Allergy. 2023; 78(1): 283–286. doi: 10.1111/all.15447 Trelnikov A, Perkins G, Yuson C, et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. J Allergy Clin Immunol. 2021; 148(1): 91–95. doi: 10.1016/j.jaci.2021.04.032 Wolfson AR, Robinson LB, Li L, et al. First-dose mRNA COVID-19 vaccine allergic reactions: Limited role for excipient skin testing. Allergy Clin Immunol Pract. 2021; 9(9): 3308–3320. doi: 10.1016/j.jaip.2021.06.010 Grieco T, Ambrosio L, Trovato F, et al. Effects of Vaccination against COVID-19 in Chronic Spontaneous and Inducible Urticaria (CSU/CIU) Patients: A Monocentric Study. J Clin Med. 2022; 11(7): 1822. doi: 10.3390/jcm11071822 Mouliou DS, Dardiotis E. Current evidence in SARS-CoV-2 mRNA vaccines and post-vaccination adverse reports: Knowns and unknowns. Diagnostics (Basel). 2022; 12(7): 1555. doi: 10.3390/diagnostics12071555 Eid E, Abdullah L, Kurban M, et al. Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol. 2021; 93(9): 5231–5232. doi: 10.1002/jmv.27036 Martinez-Reviejo R, Tejada S, Adebanjo GAR, et al. Varicella-zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: new insights. Eur J Intern Med. 2022; 104: 73–79. doi: 10.1016/j.ejim.2022.07.022 Psichogiou M, Samarkos M, Mikos N, et al. Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2. Vaccines (Basel). 2021; 9(6): 572. doi:10.3390/vaccines9060572 Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021; 385(12): 1078–1090. doi: 10.1056/NEJMoa2110475 Hertel M, Heiland M, Nahles S, et al. Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus. J Eur Acad Dermatol Venereol. 2022; 36(8): 1342–1348. doi: 10.1111/jdv.18184 Florea A, Wu J, Qian L, et al. Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023; 22(1): 643–649. doi: 10.1080/14760584.2023.2232451 Shasha D, Bareket R, Sikron FH, et al. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: Historical cohort study. Clin Microbiol Infect. 2022; 28(1): 130–134. doi: 10.1016/j.cmi.2021.09.018 Akpandak I, Miller DC, Sun Y, et al. Assessment of herpes zoster risk among recipients of COVID-19 vaccine. JAMA Netw Open. 2022; 5(11): e2242240. doi: 10.1001/jamanetworkopen.2022.42240 Birabaharan M, Kaelber DC, Karris MY. Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination; a cohort study. J Am Acad Dermatol. 2022; 87(3): 649–651. doi: 10.1016/j.jaad.2021.11.025 Patil SA, Dygert L, Galetta SL, et al. Apparent lack of association of COVID-19 vaccination with Herpes Zoster. Am J Ophthalmol Case Rep. 2022; 26: 101549. doi: 10.1016/j.ajoc.2022.101549 Ishiguro C, Mimura W, Uemura Y, et al. Multiregional population-based cohort study for evaluation of the association between herpes zoster and mRNA vaccinations for Severe Acute Respiratory Syndrome Coronavirus-2: the VENUS study. Open Forum Infect Dis. 2023; 10(7): ofad274. doi: 10.1093/ofid/ofad274 Chu CW, Jiesisibieke ZL, Yang YP, et al. Association of COVID-19 vaccination with herpes zoster: A systematic review and meta-analysis. Expert Rev Vaccines. 2022; 21(5): 601–608. doi: 10.1080/14760584.2022.2036128 Shafiee A, Amini MJ, Bahri RA, et al. Herpesviruses reactivation following COVID-19 vaccination: A systematic review and meta-analysis. Eur J Med Res. 2023; 28(1): 278. doi: 10.1186/s40001-023-01238-9 Chen IL, Chiu HY. Association of herpes zoster with COVID-19 vaccination: a systematic review and meta-analysis. J Am Acad Dermatol. 2023; 89(2): 370–371. doi: 10.1016/j.jaad.2023.03.031 Kahraman FC, Erdoğan SS, Aktaş ND, et al. Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study. J Cosmet Dermatol. 2022; 21(9): 3692–3703. doi: 10.1111/jocd.15209 Préta LH, Contejean A, Salvo F, et al. Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273). Br J Clin Pharmacol. 2022; 88(7): 3529–3534. doi: 10.1111/bcp.15280 Fathy RA, McMahon DE, Lee C, et al. Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry. J Eur Acad Dermatol Venereol. 2022; 36(1): e6–e9. doi: 10.1111/jdv.17646 Lee TJ, Lu CH, Hsieh S-C. Herpes zoster reactivation after mRNA-1273 vaccination in patients with rheumatic disease. Ann Rheum Dis. 2022; 81(4): 595–597.doi: 10.1136/annrheumdis-2021-221688 Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022; 81(5): 695–709. doi: 10.1136/annrheumdis-2021-221490 Chen J, Li F, Tian J, et al. Varicella zoster virus reactivation following COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: A cross-sectional Chinese study of 318 cases. J Med Virol. 2023; 95(1): e28307. doi: 10.1002/jmv.28307 Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomized trials. Lancet. 2021; 397(10277): 881–891. doi: 10.1016/S0140-6736(21)00432-3 Wan EYF, Chui CSL, Wang Y, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CV-2 vaccination: A self-controlled case series and nested case-control study. Lancet Reg Health West Pac. 2022; 21: 100393. doi: 10.1016/j.lanwpc.2022.100393 McMahon DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study. J Am Acad Dermatol. 2022; 86(1): 113–121. doi: 10.1016/j.jaad.2021.09.002 Larson V, Seidenberg R, Caplan A, et al. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol. 2022; 49(1): 34–41. doi: 10.1111/cup.14104 Ohsawa R, Sano H, Ikeda M, et al. Clinical and histopathological views of morbilliform rash after COVID-19 mRNA vaccination mimic those in SARS-CoV-2 virus infection-associated cutaneous manifestations. J Dermatol Sci. 2021; 103(2): 124–127. doi: 10.1016/j.jdermsci.2021.06.006 Alhammad NS, Milibary HH, Baghadi RR, et al. Morbilliform eruption after administration of second dose of Oxford/AstraZeneca vaccine. Cureus. 2022; 14(5): e24649. doi: 10.7759/cureus.24649 Khan I, Elsanousi AA, Shareef AM, et al. Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: A systematic review. Immun Inflamm Dis. 2023; 11(4): e804. doi: 10.1002/iid3.804 Jimenez-Cauhe J, Ortega-Quijano D, Carretero-Barrio I, et al. Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings. Clin Exp Dermatol. 2020; 45(7): 892–895. doi: 10.1111/ced.14281 Kim MJ, Kim JW, Kim MS, et al. Generalized erythema multiforme-like skin rash following the first dose of COVID-19 vaccine (Pfizer-Biontech). J Eur Acad Dermatol Venereol. 2021; 36(2): e98–e100. doi: 10.1111/jdv.17757 Borg L, Mercieca L, Mintoff D, et al. Pfizer-Biontech SARS-CoV-2 mRNA vaccine-associated erythema multiforme. J Eur Acad Dermatol Venereol. 2021; 36(1): e22–e24. doi: 10.1111/jdv.17682 Lefeuvre M, Kerneuzet I, Darrieux L, et al. Multisystem inflammatory syndrome with erythema multiforme-like rash in an adult after mRNA COVID-19 vaccination. Ann Dermatol Venereol. 2022; 149(3): 211–213. doi: 10.1016/j.annder.2022.02.001 Temiz SA, Abdelmaksoud A, Dursun R, et al. Pityriasis rosea following SARS-CoV-2 vaccination: A case series. J Cosmet Dermatol. 2021; 20(10): 3080–3084. doi: 10.1111/jocd.14372 Ramot Y, Nanova K, Faitatziadou S-M, et al. Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2. J Dtsch Dermatol Ges. 2022; 20(8): 1123–1124. doi: 10.1111/ddg.14784 Drago F, Ranieri E, Malaguti F, et al. Human herpesvirus 7 in patients with pityriasis rosea. Electron microscopy investigations and polymerase chain reaction in mononuclear cells, plasma and skin. Dermatology. 1997; 195(4): 374–378. doi: 10.1159/000245991 Broccolo F, Drago F, Careddu AM, et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol. 2005; 124(6): 1234–1240. doi: 10.1111/j.0022-202X.2005.23719.x Drago F, Broccolo F, Ciccarese G. Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination. Clin Dermatol. 2022; 40(5): 586–590. doi: 10.1016/j.clindermatol.2022.01.002 Petruizzi M, Galleggiante S, Messina S, et al. Oral erythema multiforme after Pfizer-Biontech COVID-19 vaccination: a report of four cases. BMC Oral Health. 2022; 22(1): 90. doi: 10.1186/s12903-022-02124-2 Su JR, Haber P, Ng CS, et al. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999–2017. Vaccine. 2020; 38(7): 1746–1752. doi: 10.1016/j.vaccine.2019.12.028 Yousefian M, Khadivi A. Occurrence of erythema multiforme following COVID-19 vaccination: a review. Clin Exp Vaccine Res. 2023; 12(2): 87–96. doi: 10.7774/cevr.2023.12.2.87 Bertolani M, de Felici Del Giudice MB, Ridolo E, et al. Skin reaction to COVID-19 vaccine: A report of 4 cases. Dermatol Reports. 2022; 14(3): 9376. doi: 10.4081/dr.2022.9376 Kong J, Cuevas-Castillo F, Nassar M, et al. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report. J Infect Public Health. 2021; 14(10): 1392–1394. doi: 10.1016/j.jiph.2021.06.021 Bakir M, Almeshal H, Alturki R, et al. Toxic epidermal necrolysis post COVID-19 vaccination—First reported case. Cureus. 2021; 13(8): e17215. doi: 10.7759/cureus.17215 Zou H, Daveluy S. Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol. 2023; 64(1): e1–e10. doi: 10.1111/ajd.13958 Dash S, Sirka CS, Mishra S, et al. COVID-19 vaccine-induced Stevens-Johnson syndrome. Clin Exp Dermatol. 2021; 46(8): 1615–1617. doi: 10.1111/ced.14784 Elboraey MO, Essa EESF. Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: A case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021; 132(4): e139–e142. doi: 10.1016/j.oooo.2021.06.019 Mansouri P, Chalangari R, Martits-Chalangari K, et al. Stevens-Johnson Syndrome due to COVID-19 vaccination. Clin Case Rep. 2021; 9(11): e05099. doi: 10.1002/ccr3.5099 Padniewski JJ, Jacobson-Dunlop E, Albadri S, et al. Stevens-Johnson syndrome precipitated by Moderna Inc. COVID-19 vaccine: A case-based review of literature comparing vaccine and drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Int J Dermatol. 2022; 61(8): 923–929. doi: 10.1111/ijd.16222 Mansouri P, Farshi S. A case of Steven-Johnson syndrome after COVID-19 vaccination. J Cosmet Dermatol. 2022; 21(4): 1358–1360. doi: 10.1111/jocd.14756 Mardani M, Mardani S, Kani ZA, et al. An extremely rare mucocutaneous adverse reaction following COVID-19 vaccination: Toxic epidermal necrolysis. Dermatol Ther. 2022; 35(5): e15416. doi: 10.1111/dth.15416 Aimo C, Mariotti EB, Corrà A, et al. Stevens-Johnson syndrome induced by Vaxvetria (AZD1222) COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2022; 36(6): e417–e419. doi: 10.1111/jdv.17988 Boualila L, Mrini B, Tagmouti A, et al. Sinopharm COVID-19 vaccine-induced Stevens-Johnson syndrome. J Fr Ophtalmol. 2022; 45(4): e179–e182. doi: 10.1016/j.jfo.2021.12.005 Seck B, Dieye A, Diallo M. Lethal toxic epidermal necrolysis probably induced by Sinopharm COVID-19 vaccine. Rev Fr Allergol (2009). 2022; 62(6): 590–592. doi: 10.1016/j.reval.2022.07.001 Kherlopian A, Zhao C, Ge L, et al. A case of toxic epidermal necrolysis after ChAdOx1 nCov-19 (AZD1222) vaccination. Australas J Dermatol. 2022; 63(1): e93–e95. doi:10.1111/ajd.13742 Patel R, Lu V. An unusual presentation of Steven-Johnson syndrome Pfizer BNT162b2 COVID-19 vaccination. J Ayub Med Coll Abbottabad. 2023; 35(1): 180–181. doi: 10.55519/JAMC-01-11097 Jue MS, Joh HC, Kim SH, et al. Stevens-Johnson Syndrome/toxic epidermal necrolysis overlap after the third dose of BNT162b2 mRNA COVID-19 vaccination and literature review. Dermatitis. 2023; 34(2): 158–159. doi: 10.1089/derm.2022.29003.msj Lo HK, Lin YC, Chen HM, et al. mRNA-1273 COVID-19 vaccine-induced Steven-Johnson syndrome. QJM. 2023; 116(3): 247–249. doi:10.1093/qjmed/hcac282 Sapsford S, Wood B. Severe cutaneous reaction to the messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) vaccine. N Z Med J. 2022; 135(1564): 72–76. da Cruz Gouveia PA, Cavalcanti LNF, Alves LCF, et al. Stevens-Johnson syndrome after ChAdOx1 nCoV-19 vaccine. Indian J Dermatol Venereol Leprol. 2022; 88(5): 702. doi: 10.25259/IJDVL_941_2021 Marcelino J, Vieira J, Ferreira F, et al. Stevens-Johnson syndrome related with Comirnaty® coronavirus disease 2019 vaccine. Asia Pac Allergy. 2022; 12(3): e30. doi: 10.5415/apallergy.2022.12.e30 Siripipattanamongkol N, Rattanasak S, Taiyaitieng C, et al. Toxic epidermal necrolysis after first dose of Pfizer-BioNTech (BNT162b2) vaccination with pharmacogenomic testing. Pediatr Dermatol. 2022; 39(4): 601–605. doi: 10.1111/pde.15074 Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist? Br J Dermatol. 2007; 156(3): 609–611. doi: 10.1111/j.1365-2133.2006.07704.x Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS) Semin Cutan Med Surg. 1996; 15(4): 250–257. doi: 10.1016/s1085-5629(96)80038-1 Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): A reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int. 2006; 55(1): 1–8. doi: 10.2332/allergolint.55.1 Lospinoso K, Nichols CS, Malachowski SJ, et al. A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine. JAAD Case Rep. 2021; 13: 134–137. doi: 10.1016/j.jdcr.2021.05.010 O'Connor T, O’Callaghan-Maher M, Ryan P, et al. Drug reaction with eosinophilia and systemic symptoms syndrome following vaccination with the AstraZeneca COVID-19 vaccine. JAAD Case Rep. 2022; 20: 14–16. doi: 10.1016/j.jdcr.2021.11.028 Korekawa A, Nakajima K, Fukushi K, et al. Three cases of drug-induced hypersensitivity syndrome associated with mRNA-based coronavirus disease 2019 vaccines. J Dermatol. 2022; 49(6): 652–655. doi: 10.1111/1346-8138.16347 Ikeda T, Yokoyama K, Kawakami T. Overlapping acute generalized exanthematous pustulosis drug reaction with eosinophilia and systemic symptoms induced by a second dose of the Moderna COVID-19 vaccine. J Dermatol. 2022; 49(12): e446–e447. doi: 10.1111/1346-8138.16541 Schroeder JW, Gamba C, Toniato A; COVID-19 Study Group; Rongioletti F. A definite case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by administration of the Pfizer/BioNTech BNT162b2 vaccine for SARS-CoV2.Clin Dermatol. 2022; 40(5): 591–594. doi: 10.1016/j.clindermatol.2022.02.018 Tay WC, Lee JSS, Chong WS. Tozinameran (Pfizer-BioNTech COVID-19 vaccine)-induced AGEP-DRESS syndrome. Ann Acad Med Singap. 2022; 51(12): 796–797. doi: 10.47102/annals-acadmedsg.2022338 Hanna M, Yang S. Eosinophilia and systemic symptoms (DRESS) Syndrome. Cureus. 2022; 14(11): e31310. doi: 10.7759/cureus.31310 Tomayko MM, Damsky W, Fathy R, et al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. J Allergy Clin Immunol. 2021; 148(3): 750–751. doi: 10.1016/j.jaci.2021.06.026 Seol JE, Ahn SW, Jang SH, et al. A case of recurrent fixed drug eruption following the administration of 2 different coronavirus disease 2019 vaccines verified using intradermal and patch tests. JAAD Case Rep. 2023; 33: 23-26. doi: 10.1016/j.jdcr.2022.08.029 Choi S, Kim SH, Hwang JH, et al. Rapidly progressing generalized bullous fixed drug eruption after the first dose of COVID-19 messenger RNA vaccination. J Dermatol. 2023; 50(9): 1190–1193. doi: 10.1111/1346-8138.16808 Gambichler T, Hamdani N, Budde H, et al. Bullous pemphigoid after SARS-CoV-2 vaccination: Spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies. Br J Dermatol. 2022; 186(4): 728–731. doi: 10.1111/bjd.20890 Calabria E, Canfora F, Mascolo M, et al. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review. Pathol Res Pract. 2022; 232: 153834. doi: 10.1016/j.prp.2022.153834 Vojdani A, Vojdani E, Melgar AL, et al. Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens. Front Immunol. 2022; 13: 1003094. doi: 10.3389/fimmu.2022.1003094 Kasperkiewicz M, Bednarek M, Tukaj S. Case Report: Circulating anti-SARS-CoV-2 antibodies do not cross-react with pemphigus or pemphigoid autoantigens. Front Med (Lausanne). 2021; 8: 807711. doi: 10.3389/fmed.2021.807711 Birabaharan M, Kaelber DC, Orme CM, et al. Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination. Br J Dermatol. 2022; 187(2): 271–273. doi: 10.1111/bjd.21240 Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020; 83(4): 1118–1129. doi: 10.1016/j.jaad.2020.06.1016 Temiz SA, Abdelmaksoud A, Dursun R, et al. Acral chilblains-like lesions following inactivated SARS-CoV-2 vaccination. Int J Dermatol. 2021; 60(9): 1152–1153. doi: 10.1111/ijd.15619 Lesort C, Kanitakis J, Donzier L, et al. Chilblains-like lesions after BNT162b2 mRNA COVID-19 vaccine: A case report suggesting that ‘COVID toes’ are due to the immune reaction to SARS-CoV-2. J Eur Acad Dermatol Venereol. 2021; 35(10): e630–e632. doi: 10.1111/jdv.17451 Holmes GA, Desai M, Limone B, et al. A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology JAAD Case Rep. 2021: 16: 53–57. doi: 10.1016/j.jdcr.2021.07.038 Meara AS, Silkowski M, Quin K, et al. A Case of Chilblains-like lesions post SARS-CoV-2 vaccine? J Rheumatol. 2021; 48(11): 1754. doi: 10.3899/jrheum.210226 Lopez S, Vakharia P, Vandergriff T, et al. Pernio after COVID-19 vaccination. Br J Dermatol. 2021; 185(2): 445–447. doi: 10.1111/bjd.20404 Kha C, Itkin A. New-onset chilblains in close temporal association to mRNA-1273 vaccination. JAAD Case Rep. 2021; 12: 12–14. doi: 10.1016/j.jdcr.2021.03.046 Shaikh TG, Waseem S, Ahmed SH, et al. SARS-CoV-2 vaccination and chilblains-like lesions: What do we know so far? Dermatol Pract Concept. 2022; 12(4): e2022170. doi: 10.5826/dpc.1204a170 Trougakos IP, Stamatelopoulos K, Terpos E, et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021; 28(1): 9. doi: 10.1186/s12929-020-00703-5 Qiao JW, Dan Y, Wolf ME, et al. Post-vaccination COVID Toes (Chilblains) Exacerbated by Rituximab Infusion Suggests Interferon Activation as Mechanism. Mil Med. 2022; 187(11-12): e1480–e1482. doi: 10.1093/milmed/usab314 Verweij CL, Vosslamber S. New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine. Discov Med. 2011; 12(64): 229–236. Di Bona D, Miniello A, Nettis E. Systemic drug-related intertriginous and flexural exanthema-like eruption after Oxford-AstraZeneca COVID-19 vaccine. Clin Mol Allergy. 2022; 20(1): 13. doi: 10.1186/s12948-022-00179-8 Chang Y, Wei W. Angiotensin II in inflammation, immunity and rheumatoid arthritis. Clin Exp Immunol. 2015; 179(2): 137–145. doi: 10.1111/cei.12467 Naor D. Editorial: Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the Activity of Inflammation and Cancer. Front Immunol. 2016; 7: 39. doi: 10.3389/fimmu.2016.00039 Munavalli GG, Knutsen-Larson S, Lupo MP, et al. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation. JAAD Case Rep. 2021; 10: 63–68. doi: 10.1016/j.jdcr.2021.02.018 Rasner CJ, Schultz B, Bohjanen K, et al. Autoimmune bullous disorder flares following severe acute respiratory syndrome coronavirus 2 vaccination: A case series. J Med Case Rep. 2023; 17(1): 408. doi: 10.1186/s13256-023-04146-y El-Qushayri AE, Nardone B. Psoriasis exacerbation after COVID-19 vaccines: A brief report of the reported cases. Dermatol Ther. 2022; 35(12): e15900. doi: 10.1111/dth.15900 Wu PC, Huang IH, Wang CW, et al. New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review. Am J Clin Dermatol. 2022; 775–799. doi: 10.1007/s40257-022-00721-z Durmaz I, Turkmen D, Altunisik N, et al. Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID-19 vaccine: A report of three cases. Dermatol Ther. 2022; 35(4): e15331. doi: 10.1111/dth.15331 Dangien A, Darbord D, Chanal J, et al. SARS-CoV-2 vaccination may trigger and exacerbate mucosal lichen planus. J Eur Acad Dermatol Venereol. 2023; 37(9): e1094–e1096. doi: 10.1111/jdv.19144 Fukaura R, Takeichi T, Ebata A, et al. COVID-19 infection- and vaccination-related exacerbation of Darier's disease in a single patient. J Dermatol. 2023; 50(6): 833–836. doi: 10.1111/1346-8138.16725 Armoni-Weiss G, Sheffer-Levi S, Horev L, et al. Exacerbation of Hailey-Hailey Disease Following SARS-CoV-2 Vaccination. Acta Derm Venereol. 2021; 101(9): adv00554. doi: 10.2340/00015555-3907 Apaydin H, Erden A, Güven SC, et al. Effects of anti-SARS-CoV-2 vaccination on safety and disease exacerbation in patients with Behçet syndrome in a monocentric cohort. Int J Rheum Dis. 2022; 25(9): 1068–1077. doi: 10.1111/1756-185X.14387 Sprow G, Afarideh M, Dan J, et al. Autoimmune Skin Disease Exacerbations Following COVID-19 Vaccination. Front Immunol. 2022; 13: 899526. doi: 10.3389/fimmu.2022.899526